Lysine-specific demethylase 2A gene expression in clear cell renal cell carcinoma and its clinical significance [post]

Xuemei Wang, Jiannan Wang, Tan Li, Xiang Li, Yixia Zhang
2020 unpublished
BackgroundOur study aimed to explore the expression of lysine-specific demethylase 2A (KDM2A) in clear cell renal cell carcinoma (ccRCC) and its relationship with clinical features of ccRCC.MethodsA total of 50 patients with ccRCC were included. KDM2A expression was assessed by real-time PCR and immunohistochemistry (IHC). The correlations of KDM2A protein expression with clinicopathological parameters and survival rate were further verified.ResultsThe KDM2A mRNA expression was significantly
more » ... as significantly higher in ccRCC tissues than para cancer samples (P<0.05). KDM2A protein was mainly expressed in the nucleus of tumor cells. Fifty (100%) of the ccRCC samples were immunopositive, 90% of which all showed high expression of KDM2A. Compared with para cancer tissues, ccRCC samples showed a larger proportion of high KDM2A expression in the overall and most stratified analysis (P<0.05). KDM2A protein expression was positively correlated with TNM stage (r = 0.307, P = 0.030), proteinuria (r = 0.385, P = 0.006), and urine erythrocyte (r = 0.307, P = 0.030). Moreover, Kaplan-Meier survival analysis revealed that higher expression of KDM2A in ccRCC patients was associated with lower survival rate (P = 0.004).ConclusionsOur findings provided the first evidence that KDM2A could be used as a promising diagnostic and prognostic biomarker in ccRCC patients.
doi:10.21203/ fatcat:uftvld3bxzccbkcn5bfexn5p54